EP2323632A1 - Quetiapin enthaltende retardtablette - Google Patents
Quetiapin enthaltende retardtabletteInfo
- Publication number
- EP2323632A1 EP2323632A1 EP09778385A EP09778385A EP2323632A1 EP 2323632 A1 EP2323632 A1 EP 2323632A1 EP 09778385 A EP09778385 A EP 09778385A EP 09778385 A EP09778385 A EP 09778385A EP 2323632 A1 EP2323632 A1 EP 2323632A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- water
- tablet
- formulation according
- meth
- organic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Definitions
- the present invention relates to a pharmaceutical composition in the form of a prolonged-release tablet containing quetiapine or a pharmaceutically acceptable salt thereof, e.g. Containing quetiapine hemifumarate as an active ingredient. Moreover, the present invention relates to a method for producing a film-coated prolonged-release tablet.
- Quetiapine is an atypical antipsychotic medication used to treat schizophrenia and mania in bipolar disorder and in the treatment of obsessive-compulsive disorder. Quetiapine is in the form of its Hemifumaratsalzes tablet as FiIm- marketed under the trade name Seroquel XR ® immediate release under the trade name Seroquel ® or prolonged release tablet.
- Quetiapine is a relatively soluble in water active substance. It is known that water-soluble active ingredients in sustained-release formulations tend to "dose dumping", according to which a relatively large amount of the active substance is released suddenly at the beginning of the release of the active substance from the sustained-release formulation Quetiapine, in particular for its hemifumarate salt (hereafter “fumarate salt”).
- WO 97/45124 discloses a sustained-release tablet containing quetiapine, wherein the retarding effect is provided by a swellable excipient, preferably by hydroxypropylmethylcellulose (hypromellose).
- a swellable excipient preferably by hydroxypropylmethylcellulose (hypromellose).
- hydrophilic matrix formulations which may optionally contain fillers such as lactose or microcrystalline cellulose and in particular pH-modifying substances.
- the tablet core contains, in addition to the active ingredient, microcrystalline cellulose and lactose monohydrate as fillers, sodium citrate as a pH modifier, magnesium stearate as a lubricant, and hypromellose as a swellable excipient.
- WO 2008/060228 discloses a further development of the prolonged-release tablet described in WO 97/45124, which is characterized in that the formulation has selected contents of quetiapine, hypromellose and sodium citrate dihydrate. It is reported that by using sodium citrate dihydrate as a pH modifying substance, the pH dependency of the solubility of the quetiapine salt used, in particular the quetiapine fumarate, in an aqueous medium can be reduced.
- WO 01/21179 discloses a granulate comprising quetiapine and a water-soluble binder for the preparation of an orally administered solution or suspension.
- a particularly preferred water-soluble binder maltodextrin is called.
- WO 03/039516 describes a capsule or tablet comprising granules containing quetiapine.
- the granules are characterized in that, in addition to quetiapine, they contain an adjuvant for improving the dispersibility of the active ingredient in an aqueous medium ("floating agent"), such as water-insoluble celluloses, for example crystalline cellulose, powder cellulose and low-substituted hydroxypropyl cellulose, Sodium alginate, propylene glycol alginate, tragacanth and xanthan gum.
- floating agent aqueous medium
- water-insoluble celluloses for example crystalline cellulose, powder cellulose and low-substituted hydroxypropyl cellulose, Sodium alginate, propylene glycol alginate, tragacanth and xanthan gum.
- WO 2004/012699 discloses a quetiapine-containing sustained-release dosage form.
- the retarding effect is achieved in that the water-soluble active ingredient quetiapine together with a hydrophobic excipient in microparticles, which in turn are coated with a hydrophobic film. These film-coated microparticles can then be pressed into tablets.
- the microparticles are prepared by granulating the active ingredient with the hydrophobic adjuvant and using an organic solvent.
- WO 2005/041935 discloses quetiapine-containing prolonged-release tablets, which are characterized in that the active ingredient in a hydrophobic matrix consists of a
- Wax material is present.
- Waxes within the meaning of WO 2005/041935 are materials which are solid at room temperature and have melting points between 30 ° C. and 100 ° C., such as neutral or synthetic waxes, long-chain alcohols (for example lauryl alcohol), fatty acids, fatty acid esters, hydrocarbons and like.
- the sustained-release tablets are prepared by a melt granulation process by melting the wax material in the presence of the active ingredient.
- WO 2007/086079 discloses a quetiapine-containing sustained-release formulation comprising a pore-forming agent and a retarding agent.
- the retardant is hypromellose and the pore former is sodium chloride, wherein the tablet described additionally contains lactose or microcrystalline cellulose as a filler and is prepared by wet granulation using polyvinylpyrrolidone as a binder.
- WO 2007/133583 claims a sustained release formulation for water-soluble active substances such as quetiapine.
- the formulation described comprises a matrix core of a hydrophobic material and optionally other adjuvants, including fillers containing the active ingredient, and a retarding film coating containing a hydrophobic polymer and a hydrophilic pore-forming agent.
- the Matrix-forming hydrophobic materials are z. Ethylcellulose, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate and poly (meth) acrylates.
- hydrophilic pore images preferably hypromellose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone and polyalkylene glycol are used. Fillers within the meaning of WO 2007/133583 are on the one hand the
- binders and auxiliaries which function as flow regulators or improve the compressibility of the powder material.
- WO 2008/090569 relates to a sustained release formulation for an active substance having a solubility dependent on the pH of the dissolution medium solubility, such.
- Quetiapine the composition comprising a polymer controlling the release rate of the active agent in an acidic environment and a release rate controlling system, the system controlling the release of the active agent in both an acidic and a basic environment, and from a swelling agent and a the means of swelling support exists.
- the object underlying the invention was to provide a further sustained release formulation for quetiapine or a pharmaceutically acceptable salt thereof, in particular for the fumarate salt, which provides a sufficient retarding effect and in which no "dose dumping" occurs ,
- the present invention relates to a matrix formulation in the form of a sustained-release tablet comprising (a) quetiapine or a pharmaceutically acceptable salt thereof as an active ingredient, (b) at least one matrix-forming, water-insoluble and non-swellable excipient and (c) at least one water-soluble binder.
- water-insoluble auxiliaries are substances which have a solubility in water of ⁇ 10 g / L, preferably ⁇ 5 g / L, or ⁇ 1 g / L, more preferably ⁇ 0.5 g / L, even more preferably ⁇ 0.1 g / L and most preferably have ⁇ 0.01 g / L at 20 ° C.
- water-soluble binders are those which have a solubility at 20 ° C., wherein 1 part by weight of binder is soluble in ⁇ 10 parts by weight, preferably ⁇ 5 parts by weight, more preferably ⁇ 3 parts by weight and most preferably ⁇ 1 part by weight of water ,
- the water-insoluble and non-swellable adjuvant is selected from organic and inorganic adjuvants, wherein the organic adjuvant is selected from either the group of polymers or non-polymers.
- the present invention relates to a matrix formulation in the form of a sustained-release tablet, wherein the matrix-forming, water-insoluble and non-swellable excipient is an organic adjuvant and from the polymers polyvinyl acetate, cellulose esters such as cellulose acetate, cellulose propionate and cellulose acetate butyrate, alkylcelluloses such as ethylcellulose, neutral homo and copolymers of (meth) acrylic acid esters such as polymethyl (meth) acrylate, poly methyl (meth) acrylate, polybutyl (meth) acrylate, polyisobutyl (meth) acrylate and the like, cationic homo- and copolymers of (meth) acrylic acid esters with quaternary ammonium groups such as ethyl acrylate / methyl acrylate copolymer with quaternary ammonium groups (eg Eudragit RL or Eudragit RS) is selected.
- polyvinyl acetate
- the forming matrix, water-insoluble and non-swellable polymer may be polyvinyl acetate, which is for example marketed in admixture with the water-soluble binder povidone under the trade name Kollidon ® SR, or cellulose acetate, preferably together with the water-soluble binder maltodextrin or Kollicoat ® IR, be used.
- the present invention relates to a matrix formulation in the form of a prolonged-release tablet, wherein the at least one matrix-forming, water-insoluble and non-swellable adjuvant is an inorganic adjuvant selected from carbonates, phosphates and sulfates.
- the inorganic adjuvant is selected from calcium hydrogen phosphate, calcium phosphate, calcium carbonate and calcium sulfate, with calcium hydrogen phosphate and calcium phosphate being preferred.
- the present invention relates to a matrix formulation in the form of a prolonged-release tablet, wherein the at least one matrix-forming, water-insoluble and non-swellable adjuvant is an organic non-polymer, preferably a carboxylic acid.
- the organic adjuvant is fumaric acid.
- the prolonged-release tablet according to the invention preferably contains one or more water-soluble binders which consist of maltodextrin, mannitol, xylitol, pregelatinized starch, sucrose, polyvinylpyrrolidone (povidone), polyethylene glycol col / polyvinyl alcohol graft polymer (z. B. Kollicoat IR) and vinylpyrrolidone / vinyl acetate copolymers, also known as copovidone designated (z. B. Plasdone ® S-630 Copovidone), are selected.
- water-soluble binders consist of maltodextrin, mannitol, xylitol, pregelatinized starch, sucrose, polyvinylpyrrolidone (povidone), polyethylene glycol col / polyvinyl alcohol graft polymer (z. B. Kollicoat IR) and vinylpyrrolidone / vinyl acetate copolymers, also known as copovidone designated
- organic adjuvant polyvinyl acetate with the water-soluble binding agent povidone the organic adjuvant cellulose acetate butyrate with the water-soluble binder maltodextrin,
- the mass ratio of the at least one matrix-forming, water-insoluble and non-swellable adjuvant to the at least one water-soluble binder in the matrix formulation according to the invention is in particular 1: 1 to 20: 1, preferably 2: 1 to 15: 1, preferably 3: 1 to 10: 1, more preferably 3.5: 1 to 8: 1, and most preferably 4: 1 to 6: 1.
- the matrix formulation according to the invention is a film-coated prolonged-release tablet in a preferred embodiment.
- a particularly preferred embodiment of the matrix formulation according to the invention is a sustained-release tablet which is optionally film-coated, the tablet or tablet core consisting exclusively of (a) quetiapine or a pharmaceutically acceptable salt thereof as an active ingredient, (b) at least one, water-insoluble and forming the matrix non-swellable adjuvant, (c) at least one water-soluble binder and optionally (d) at least one lubricant is or is produced.
- the matrix formulation according to the invention is a prolonged-release tablet which is optionally film-coated, it usually contains no disintegrants.
- Magnesium stearate, calcium stearate, sodium stearyl fumarate, hydrogenated castor oil, talc, silica such as, for example, magnesium stearate, calcium stearate, sodium stearyl fumarate, hydrogenated castor oil, talc, silica such as, for example, can be used as a lubricant for improving the flow properties or the flowability of the powders or granules used in the preparation of the matrix formulation according to the invention.
- colloidal silica (anhydrous) and the like can be used.
- the matrix formulation according to the invention in the form of a film-coated slow-release tablet has a film coating, the film preferably comprising a water-insoluble and non-swellable film-forming agent.
- the film former is an organic polymer which is preferably composed of polyvinyl acetate, cellulose esters such as cellulose acetate, cellulose acetate propionate, cellulose acetate butyrate, alkylcelluloses such as ethylcellulose, homo- and copolymers of (meth) acrylic esters such as polymethyl (meth) acrylate, polyethylene ( meth) acrylate, polybutyl (meth) acrylate, polyisobutyl (meth) acrylate, ethyl acrylate / methyl methacrylate copolymer (eg. B.
- polyvinyl acetate cellulose esters such as cellulose acetate, cellulose acetate propionate, cellulose acetate butyrate
- alkylcelluloses such as ethylcellulose
- homo- and copolymers of (meth) acrylic esters such as polymethyl (meth) acrylate, polyethylene ( meth) acrylate, polybutyl (meth
- Kollicoat ® EMM 30 D Kollicoat ® EMM 30 D
- cationic homo- and copolymers of (meth) acryl Acidestern with quaternary Ammonium groups such as ethyl acrylate / methyl acrylate copolymer having quaternary ammonium groups (eg Eudragit RL or Eudragit RS) is selected, with cellulose acetate butyrate and cellulose acetate being particularly preferred.
- the film contains a water-soluble pore former in addition to the water-insoluble and non-swellable film former.
- the water-soluble pore-forming agent is preferably selected from organic polymers such as methylcellulose, hydroxyalkylcelluloses, e.g. As hydroxypropylmethylcellulose (hypromellose), hydroxyethylcellulose and hydroxypropylcellulose, sodium carboxymethylcellulose, polyethylene glycol, polyvinyl alcohol, polyethylene glycol / polyvinyl alcohol graft polymer (z. B.
- organic polymers such as methylcellulose, hydroxyalkylcelluloses, e.g. As hydroxypropylmethylcellulose (hypromellose), hydroxyethylcellulose and hydroxypropylcellulose, sodium carboxymethylcellulose, polyethylene glycol, polyvinyl alcohol, polyethylene glycol / polyvinyl alcohol graft polymer (z. B.
- Kollicoat IR ® polyvinylpyrrolidone (povidone), and vinylpyrrolidone / vinyl acetate copolymer (copovidone), and organic and inorganic non-polymers such as sucrose, glucose, lactose, fructose, mannitol, sorbitol, mannose, galactose and alkali metal salts, e.g. Lithium carbonate, sodium chloride, potassium chloride, potassium phosphate, sodium acetate and sodium citrate.
- Particularly preferred water-soluble pore-forming agents are polyethylene glycol / polyvinyl alcohol graft polymers, such as.
- Kollicoat IR ® and vinylpyrrolidone / vinyl acetate copolymer (copovidone).
- the sustained-release tablet according to the invention may have a separating layer between the tablet core and the coating.
- This release layer is necessary if components of the tablet core should interact with constituents of the coating. So z. B. found that the water-soluble pore former contained in the coating Kollicoat ® IR is sensitive to acid and interacts with the fumaric acid optionally contained in the tablet core.
- the release layer can be applied to the tablet cores by conventional coating methods, whereby water and / or conventional organic solvents can be used for the coating solution.
- the separation layer consists of pharmaceutically acceptable, water-soluble or rapidly disintegrating inert substances commonly used for film coating applications, such as e.g.
- sugar alcohols such as mannitol, polyethylene glycol, polyvinylpyrrolidone, vinylpyrrolidone / vinyl acetate copolymers (copovidone), polyvinyl alcohol, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, talc and the like.
- the matrix formulation according to the invention can be prepared by direct tabletting as well as by wet or dry granulates.
- the at least one, the matrix-forming, water-insoluble and non-swelling excipient is preferably intragranular together with the active ingredient and no further pharmaceutically acceptable excipients, in particular no filler or diluent, are contained in the granules.
- the at least one, the matrix-forming, water-insoluble and non-swellable excipient may also be extragranular.
- the active ingredient is granulated with a filler.
- fillers z.
- cellulose powder mannitol, various starches such. Corn starch, microcrystalline cellulose, silicified microcrystalline cellulose, sorbitol, dextrose, lactitol, lactose (anhydrous or as monohydrate) and the like.
- a suitable microcrystalline cellulose can be added to the tablet mass, in the event that the preparation according to the invention is prepared by direct tabletting.
- the present invention relates to the use of at least one matrix-forming, water-insoluble and non-swellable adjuvant and at least one water-soluble binder for preparing a matrix formulation containing quetiapine or a pharmaceutically acceptable salt thereof, wherein the matrix formulation is preferably a granule or a tablet.
- the present invention also relates to a method for producing a matrix formulation according to the invention in the form of a film-coated prolonged-release tablet, the method comprising the steps:
- step (i) dissolving the water-insoluble and non-swellable film former in a first halogen-free organic solvent
- step (ii) dissolving the water-soluble pore-forming agent in a homogeneous solvent system of water and a second halogen-free organic
- step (ii) mixing the solution of step (i) and the solution from step (ii) to obtain a homogeneous coating solution
- step (iv) applying the homogeneous coating solution to the tablet core or the separating layer surrounding the tablet core.
- the water-insoluble and non-swellable film-forming agents cellulose acetate butyrate or cellulose acetate, and the first halogen-free organic solvent is acetone and the water-soluble pore-forming agent is a polyethylene glycol / polyvinyl alcohol graft polymer (z. B. Kollicoat ® IR) and the second halogen-free organic solvent is ethanol ,
- the retarding effect of the matrix formulation according to the invention in the form of a prolonged-release tablet or film-coated prolonged-release tablet is due to the formation of a hydrophobic matrix from which the hydrophilic active ingredient quetiapine passes through the hydrophilic solid bridges Form the hydrophobic matrix particles during granulation or direct compression and consist essentially of the water-soluble binder is discharged continuously and slowly. It has surprisingly been found that the tablet core itself, ie in the absence of a retarding film coating, has a retarding effect. Examples
- the release rates of quetiapine from the tablets of the invention and from the Seroquel ® -Retardtabletten (Comparative tablets) of the strengths of 50 mg, 200 mg, 300 mg and 400 mg were dissolved in a 0.1 N aqueous solution of hydrochloric acid (in an aqueous acetate buffer, pH 4.5 ) or in an aqueous phosphate buffer (pH 6.8) at a stirrer speed of 100 rpm and a temperature of 37 ° C. ⁇ 0.5 ° C. according to "European Pharmacopoeia 6.0", 2.9.3., They are the amount released Active ingredient [%] per time [h].
- Microcrystalline cellulose (Avicel ® PH 102) 15.61
- Kollidon * SR consists of 80% polyvinyl acetate and 19% povidone Method:
- the ingredients of the dry mix except magnesium stearate were sieved and mixed. Subsequently, the magnesium stearate was added and the resulting tablet mass was mixed and pressed into a tablet core. The tablet core was then coated with Opadry.
- Microcrystalline cellulose (Avicel ® PH 101) 63.48 63.48
- Ethylcellulose (Ethocel Standard 7 Premium) 6.00 5.50
- Hypromellose (Methocel premium 5 cps) 8,50 8,00
- Kollidon * SR consists of 80% polyvinyl acetate and 19% povidone Method:
- Quetiapinftimarate and microcrystalline cellulose were mixed and granulated with an aqueous povidone solution.
- the wet granules thus obtained were subjected to rapid drying until the drying loss was below 2%.
- the dried granules were screened and blended with the extragranular ingredients Kollidon ® SR and sodium.
- the tablet mixture thus obtained was pressed into a tablet core, which was then coated with a coating solution.
- the coating solution was prepared by dispersing Ethocel in dibutyl phthalate-containing isopropyl alcohol. Hypromellose was added to the resulting dispersion. The dispersion was stirred and water was added until a clear solution was obtained. The solution was then filtered to remove any non-soluble components from the coating solution.
- Hypromellose (Methocel premium 5 cps) 5,50
- Quetiapine fumarate and anhydrous calcium hydrogen phosphate were mixed and contacted with an aqueous povidone-containing granulation solution.
- the moist granules thus obtained were subjected to rapid drying, to a drying loss below 2%.
- the dried granules were mixed with magnesium stearate and compressed into a tablet.
- the tablet core was coated with a coating solution prepared as indicated in Example 2.
- Quetiapine fumarate and anhydrous calcium hydrogen phosphate were mixed and granulated with an aqueous maltodextrin solution.
- the wet granules thus obtained were dried to quick drying to a drying loss of less than 2%.
- the dried granules were sieved and mixed with magnesium stearate as an extra-granular component, the resulting tablet mass was then ve ⁇ resst to a tablet core.
- the coating solution was prepared by adding cellulose acetate butyrate were dissolved in acetone and Kollicoat IR ® in water, wherein the aqueous Kollicoat ® IR-solution was then added with stirring to anhydrous ethanol.
- Microcrystalline cellulose (Avicel ® PH 102) 57.61
- Kollidon * SR consists of 80% polyvinyl acetate and 19% povidone
- the tablet was prepared as indicated in Example 1.
- the tablet was prepared as indicated in Example 4, except that it is not an aqueous Kollicoat IR-solution was added to ethanol, but an aqueous Kollicoat ® IR-solution was added with anhydrous ethanol. In addition, the cellulose acetate butyrate acetone solution was added slowly and with stirring to the Kollicoat ® IR solution. Release profile of the extended release tablet of Example 5 and Example 6 compared with Seroquel ® 300 mg prolonged-release tablet (0.1 N hydrochloric acid solution)
- the tablet was prepared as indicated in Example 6. Release profile of the prolonged-release tablet from Example 7 in comparison to the Seroquel SO mg prolonged-release tablet (0.1 N hydrochloric acid solution)
- Quetiapinfiimarate and fumaric acid were sieved and mixed.
- the mixture was granulated with an aqueous maltodextrin solution.
- the wet granules were flash dried until the drying loss was below 2%.
- the dried granules were sieved, mixed with magnesium stearate and pressed into a tablet core. Subsequently, the tablet core was coated, whereby the coating solution was prepared as indicated in Example 6.
- the tablet was prepared as indicated in Example 6, using methylene chloride instead of acetone to prepare the coating solution and using isopropyl alcohol instead of ethanol. Release profile of the prolonged-release tablet from Example 9 in comparison to the Seroquel 300 mg prolonged-release tablet (0.1 N hydrochloric acid solution)
- the tablet was prepared as described in Example 7. Release profile of the extended release tablet of Example 10 in comparison to the sero- quel ® 300 mg prolonged-release tablet and the extended release tablet of Example 6 (0.1 N hydrochloric acid solution)
- the tablet was prepared as described in Example 8. Release profile of the extended release tablet of Example 11 in comparison to the sero- quel ® 300 mg prolonged release (while changing the pH of the release medium)
- the tablet was prepared as in Example 7, with part of the anhydrous calcium hydrogen phosphate used being replaced by fumaric acid. Release profile of the extended release tablet of Example 12 in comparison to the sero- quel ® 50 mg prolonged-release tablet and the extended release tablet of Example 7 (phosphate buffer (pH 6.8))
- the tablet was prepared as indicated in Example 8. Release profile of the extended release tablet of Example 13 in comparison to the sero- quel ® 400 mg prolonged-release tablet (0.1 N hydrochloric acid solution)
- the tablet was prepared as described in Example 8, wherein in the coating cellulose acetate butyrate replaced by cellulose acetate and Kollicoat IR ® by copovidone and acetone was used as the sole coating solvent. Release profile of the prolonged release tablet from Example 14 in comparison to the Seroquel ® 200 mg prolonged-release tablet ((acetate buffer pH 4.5))
- Quetiapine fumarate and fumaric acid were sieved and mixed.
- the mixture was granulated with an aqueous maltodextrin solution.
- the wet granules were flash dried until the drying loss was below 2%.
- the dried granules were sieved, mixed with magnesium stearate and pressed into a tablet core.
- the release layer was prepared by milling the talc in the presence of water to obtain a colloidal dispersion, which was then added to a solution of copovidone and mannitol in water with stirring.
- the resulting coating solution in the form of a colloidal dispersion was then applied to the tablet core.
- the coating solution was prepared by dissolving cellulose acetate in acetone and Kollicoat IR in purified water, followed by adding anhydrous ethanol to the aqueous Kollicoat IR solution with stirring. After that, the Kollicoat ® IR solution was slowly added to the cellulose acetate acetone solution. The resulting solution was stirred until a clear solution was obtained, which in turn was filtered to obtain a homogeneous coating solution free of insoluble components. Subsequently, the coating solution thus obtained was coated on the tablet core with the release layer.
- Quetiapine fumarate and fumaric acid were sieved and mixed.
- the cellulose acetate was dissolved in acetone and Kollicoat IR ® in a solvent mixture of anhydrous ethanol and purified water. Then, the solutions thus obtained were mixed to obtain a granulating liquid.
- the mixture of quetiapine fumarate and fumaric acid was mixed with the thus obtained
- Granulating fluid granulated The wet granules were flash dried until the drying loss was below 2%. The dried granules were sieved, mixed with magnesium stearate and compressed into a tablet. Release profile of the prolonged release tablet of example 16 in comparison to the Seroquel ® 200 mg prolonged-release tablet ((acetate buffer pH 4.5))
- the tablet was prepared as described in Example 8, wherein in the coating cellulose acetate butyrate replaced by cellulose acetate and Kollicoat IR ® by copovidone and acetone was used as the sole coating solvent. Release profile of the extended release tablet of Example 17 in comparison to the Seroquel ® 200 mg prolonged-release tablet (0.1 N hydrochloric acid solution)
- Quetiapine fumarate, fumaric acid and cellulose acetate were sieved and mixed. Copovidone was dissolved in a mixed solvent of acetone and purified water to obtain a granulating liquid. The mixture of quetiapine fumarate, fumaric acid and cellulose acetate was granulated with the granulating liquid thus obtained. The wet granules were flash dried until the drying loss was below 2%. The dried granules were sieved, mixed with magnesium stearate and compressed into a tablet. Release profile of the prolonged release tablet from Example 18 in comparison to the Seroquel ® 200 mg prolonged-release tablet ((acetate buffer pH 4.5))
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE200810046650 DE102008046650A1 (de) | 2008-09-10 | 2008-09-10 | Quetiapin enthaltende Retardtablette |
PCT/EP2009/006496 WO2010028794A1 (de) | 2008-09-10 | 2009-09-08 | Quetiapin enthaltende retardtablette |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2323632A1 true EP2323632A1 (de) | 2011-05-25 |
Family
ID=41259833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09778385A Withdrawn EP2323632A1 (de) | 2008-09-10 | 2009-09-08 | Quetiapin enthaltende retardtablette |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2323632A1 (de) |
DE (1) | DE102008046650A1 (de) |
WO (1) | WO2010028794A1 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010089259A2 (en) * | 2009-02-04 | 2010-08-12 | Woerwag R&D Gmbh | Sustained release composition containing quetiapine |
US20100303920A1 (en) * | 2009-05-27 | 2010-12-02 | Johan Hjartstam | Aqueous Film Coating Composition / 841 |
WO2011154118A1 (en) * | 2010-06-07 | 2011-12-15 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Quetiapine prolonged-release tablets |
DE102010033527A1 (de) * | 2010-08-05 | 2012-02-09 | Acino Pharma Ag | Quetiapin-Tabletten |
CN101912374B (zh) * | 2010-08-08 | 2016-01-20 | 浙江华海药业股份有限公司 | 喹硫平缓释片及其制备方法 |
WO2013074048A2 (en) | 2011-08-08 | 2013-05-23 | Mahmut Bilgic | Tablet forms comprising quetiapine fumarate |
DE102011115690A1 (de) | 2011-10-11 | 2013-04-11 | Acino Pharma Ag | Quetiapin enthaltende Formulierungen |
CN102335155B (zh) * | 2011-10-17 | 2013-03-27 | 苏州大学 | 一种富马酸喹硫平缓释片及其制备方法 |
WO2013100879A1 (en) * | 2011-12-27 | 2013-07-04 | Mahmut Bilgic | Pharmaceutical compositions comprising quetiapine |
RU2588840C1 (ru) * | 2015-03-26 | 2016-07-10 | Общество с ограниченной ответственностью ООО "ВАЛЕНТА-ИНТЕЛЛЕКТ" | Таблетки кветиапина с пролонгированным высвобождением и способ их получения |
EP3199167A1 (de) | 2016-01-28 | 2017-08-02 | G.L. Pharma GmbH | Arzneimittel zur behandlung von eisenmangelzuständen mit folsäuredefizit |
EP3199145B1 (de) | 2016-01-28 | 2018-10-17 | G.L. Pharma GmbH | Stabilisierte formulierung eines folsäure/eisen-präparats |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
GB9611328D0 (en) | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
GB9922271D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
DE10029201A1 (de) * | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
EP1448169A1 (de) | 2001-11-07 | 2004-08-25 | Fujisawa Pharmaceutical Co., Ltd. | Methode zur verbesserung der löslichkeit von schwer-dispergierbaren medikamenten |
US8216609B2 (en) | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
JP2007509155A (ja) | 2003-10-21 | 2007-04-12 | アルファーマ インコーポレイテッド | クエチアピンを含有する薬剤 |
WO2005065641A2 (en) * | 2004-01-06 | 2005-07-21 | Panacea Biotec Ltd. | Non-disintegrating oral solid composition of high dose of water soluble drugs |
US20100178333A1 (en) | 2006-01-25 | 2010-07-15 | Astron Research Limited | Sustained release dosage form of phenothiazine derivatives containing channelizer |
EP2457563B1 (de) | 2006-05-09 | 2017-03-22 | Mallinckrodt LLC | Feste Darreichungsformen mit modifizierter Freisetzung nullter Ordnung |
US20090324717A1 (en) * | 2006-07-28 | 2009-12-31 | Farmaprojects, S. A. | Extended release pharmaceutical formulation of metoprolol and process for its preparation |
PT103884A (pt) | 2006-11-17 | 2008-05-19 | Astrazeneca Ab | Composições de libertação prolongada e métodos para a sua preparação |
WO2008090569A1 (en) | 2007-01-25 | 2008-07-31 | Panacea Biotec Ltd | Modified release pharmaceutical composition and a process of making the same |
US20110052648A1 (en) * | 2008-03-12 | 2011-03-03 | Avi Avramoff | Oral modified-release formulations containing thiazepines |
-
2008
- 2008-09-10 DE DE200810046650 patent/DE102008046650A1/de not_active Ceased
-
2009
- 2009-09-08 EP EP09778385A patent/EP2323632A1/de not_active Withdrawn
- 2009-09-08 WO PCT/EP2009/006496 patent/WO2010028794A1/de active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2010028794A1 * |
Also Published As
Publication number | Publication date |
---|---|
DE102008046650A1 (de) | 2010-03-11 |
WO2010028794A1 (de) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2323632A1 (de) | Quetiapin enthaltende retardtablette | |
DE60121857T2 (de) | Arzneimittelzusammensetzung mit verzögerter Wirkstoffabgabe | |
EP1830855B1 (de) | Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung | |
EP1110544B1 (de) | Verfahren zur Herstellung einer geschmacksmaskierten oralen Darreichungsform& x9; | |
DE69833490T2 (de) | Orale pharmazeutische zusammensetzung enthaltend ein benzimidazolderivat mit antiulcus wirkung und verfahren zu seiner herstellung | |
DE19940944B4 (de) | Retardierte, orale, pharmazeutische Darreichungsformen | |
DE69434479T2 (de) | Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe | |
DE60222687T3 (de) | Pharmazeutische zusammensetzungen enthaltend mycophenolsäure oder ein mycophenolat salz | |
EP1113787B1 (de) | Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung | |
CH648484A5 (de) | Pharmazeutische zubereitung eines festen medikamentmaterials. | |
CA2216215A1 (en) | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity | |
EP1140031B1 (de) | Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff | |
WO2012010669A2 (de) | Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer | |
EP1017392B1 (de) | Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung | |
CH705273B1 (de) | Pharmazeutische Zusammensetzung – umfassend Hydromorphon und Naloxon. | |
DE202009018024U1 (de) | Quetiapin-Zusammensetzung | |
DE602004006443T2 (de) | Beschichtete minitabletten von venlafaxinhydrochlorid mit verlängerter freisetzung | |
WO2002000219A1 (de) | Retard-zubereitungen von chinolon-antibiotika und verfahren zu ihrer herstellung | |
JP4540092B2 (ja) | 酸に不安定な生理活性化合物を含有する製剤組成物及びその製法 | |
WO2009056266A2 (de) | Candesartancilexetil | |
WO2006084684A1 (de) | Pharmazeutische zusammensetzungen nebivolo und ein hydrophiles polymer | |
DE60035579T2 (de) | Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme | |
DE60037897T2 (de) | Orales arzneimittel mit verzögerter wirkstoffabgabe | |
WO1990006107A1 (en) | Sustained release diltiazem formulation | |
DE602005004164T2 (de) | Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110223 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: RUCHATZ, DIETER Inventor name: LAL PASAHN, MANOHAR Inventor name: BALA RAMESHA CHARY, RALLABANDI Inventor name: YOGANANDA GUJJAR, CHAITANYA |
|
17Q | First examination report despatched |
Effective date: 20110804 |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130403 |